AU Patent

AU2013204034A1 — Azaindole derivatives as kinase inhibitors

Assigned to Ariad Pharmaceuticals Inc · Expires 2013-05-02 · 13y expired

What this patent protects

H: \ms\[iitenvovc,\NRPonblxDCC\RXS\5O68926_1.doc-1/04/2013 Abstract This invention relates to compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use. BN-X (Rd') (I) ' 2 (Ra). (RO)s

USPTO Abstract

H: \ms\[iitenvovc,\NRPonblxDCC\RXS\5O68926_1.doc-1/04/2013 Abstract This invention relates to compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use. BN-X (Rd') (I) ' 2 (Ra). (RO)s

Drugs covered by this patent

Patent Metadata

Patent number
AU2013204034A1
Jurisdiction
AU
Classification
—
Expires
2013-05-02
Drug substance claim
No
Drug product claim
No
Assignee
Ariad Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.